ライフサイエンスコーパス: conserving surgery

1 treated with radiotherapy (RT) after breast-conserving surgery.

2 nodes and had completed mastectomy or breast-conserving surgery.

3 changing from radical nephrectomy to nephron-conserving surgery.

4 andard whole-breast irradiation after breast-conserving surgery.

5 ng of TAM and radiotherapy (RT) after breast-conserving surgery.

6 in stage II BC patients treated with breast conserving surgery.

7 .37) were the strongest predictors of breast-conserving surgery.

8 stics were associated with the use of breast-conserving surgery.

9 esponded and 48% underwent successful breast-conserving surgery.

10 was given to 86% of patients who had breast-conserving surgery.

11 e as likely as other women to undergo breast-conserving surgery.

12 ss likely than other women to undergo breast-conserving surgery.

13 ransient effect on the rate of use of breast-conserving surgery.

14 All had had breast-conserving surgery.

15 influences local recurrence following breast-conserving surgery.

16 fit from neoadjuvant therapy enabling breast-conserving surgery.

17 traoperative margin assessment during breast-conserving surgery.

18 nical application of gGlu-HMRG during breast-conserving surgery.

19 ajority of patients (76.1%) underwent breast-conserving surgery.

20 breast tissue is an important step in breast-conserving surgery.

21 tion of residual cancer tissue during breast-conserving surgery.

22 bmitted for surgery, and 10 underwent breast-conserving surgery.

23 r intraoperative margin assessment in breast-conserving surgeries.

24 tential intraoperative use in guiding breast-conserving surgeries.

25 orbidity for mastectomies (4.0%) than breast conserving surgery (1.6%, P < 0.001).

26 erienced no recurrence, 963 underwent breast-conserving surgery, 263 mastectomy without reconstructio

27 vasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral mastectom

28 vasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral mastectom

29 After breast-conserving surgery, 90% of local recurrences occur withi

30 For those who have undergone breast-conserving surgery, a post-treatment mammogram should be

31 For women who have undergone breast-conserving surgery, a post-treatment mammogram should be

32 omissions of radiation therapy after breast-conserving surgery, adjuvant chemotherapy after resectio

33 00-12.50 Gy/4-5 fractions]) following breast-conserving surgery administered in community-based and a

34 pport the treatment of MO tumors with breast conserving surgery after a detailed clinical evaluation.

35 mpact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy has no

36 on, we determined whether the rate of breast-conserving surgery after the legislation was different f

37 rall survival advantage compared with breast-conserving surgery alone.

38 xamined the trend over time in use of breast-conserving surgery among patients in four sites (Connect

39 in both states and the correlates of breast-conserving surgery among women eligible for the procedur

40 to 1.73), but less likely to undergo breast-conserving surgery among women undergoing definitive sur

41 ative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatment resu

42 e breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to unde

43 ults of studies of radiotherapy after breast-conserving surgery and after mastectomy, and an interpre

44 paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissection, w

45 These results support the use of breast-conserving surgery and definitive breast irradiation for

46 treatment of DCIS of the breast using breast-conserving surgery and definitive breast irradiation.

47 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) underwent a

48 men have with various providers about breast-conserving surgery and mastectomy.

49 9 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by approxi

50 ast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherap

51 or younger at diagnosis treated with breast-conserving surgery and radiation therapy (> or = 60 Gy)

52 d with LR among patients treated with breast-conserving surgery and radiation therapy.

53 cancer patients who were treated with breast-conserving surgery and radiation were analyzed.

54 We compared the outcome of breast-conserving surgery and radiotherapy in BRCA1/2 mutation

55 For patients treated with breast-conserving surgery and RT, the 5-year cumulative inciden

56 All 5210 patients underwent breast-conserving surgery and SLN dissection.

57 ed with vs without the RT boost after breast-conserving surgery and WBRT.

58 ot both, were permitted), who had had breast-conserving surgery and were receiving adjuvant endocrine

59 an half (56%) of the women who had fertility-conserving surgery and who have been in remission at lea

60 658 women who had undergone breast-conserving surgery and who were receiving adjuvant endoc

61 carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT).

62 d, 20% do not receive radiation after breast-conserving surgery, and 30% to 70% of women with lymph n

63 the likelihood that women will choose breast-conserving surgery, and enhances patient knowledge of tr

64 re DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or without th

65 th older age, total mastectomy versus breast-conserving surgery, and reconstructive surgery.

66 f persons undergoing cholecystectomy, breast-conserving surgery, anterior cruciate ligament reconstru

67 mal mortality, recurrence rates after breast-conserving surgery are significant, and half are invasiv

68 e (n = 124), 44% of patients received breast-conserving surgery (BCS) after anastrozole compared with

69 tients with invasive cancer receiving breast-conserving surgery (BCS) and among patients undergoing m

70 adical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (RT).

71 99, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for ductal car

72 breast cancer patients, treated with breast-conserving surgery (BCS) and whole-breast irradiation (W

73 f Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while mastec

74 may decrease the reoperation rate in breast-conserving surgery (BCS) compared with rates after surge

75 ists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (D

76 psilateral breast events (IBEs) after breast-conserving surgery (BCS) for ductal carcinoma in situ (D

77 ase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-posi

78 d for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the treatme

79 my was performed in 1464 patients and breast-conserving surgery (BCS) in 1395.

80 These 25,000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherapy (gene

81 Breast conserving surgery (BCS) is a recommended treatment for

82 Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option

83 PURPOSE Breast-conserving surgery (BCS) is an effective treatment for d

84 Although breast-conserving surgery (BCS) is often assumed to result in m

85 breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is relatively high.

86 ase for women with DCIS who underwent breast-conserving surgery (BCS) or mastectomy.

87 cted rates of radiation therapy after breast-conserving surgery (BCS) suggest undertreatment.

88 ume surgeons were more likely to have breast-conserving surgery (BCS) than those managed by low-volum

89 Guidelines recommend breast-conserving surgery (BCS) with radiation or mastectomy fo

90 CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastect

91 st for early stage breast cancer: (1) breast conserving surgery (BCS), (2) mastectomy with reconstruc

92 Strategies were breast-conserving surgery (BCS), BCS with 50-Gy radiation (RT)

93 ing NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (BLM), an

94 he risk of local recurrence following breast-conserving surgery (BCS), even in "low-risk" populations

95 ring partial-breast irradiation after breast-conserving surgery (BCS).

96 have a choice between mastectomy and breast conserving surgery (BCS).

97 wire-guided localization (WGL) after breast conserving surgery (BCS).

98 o not receive radiation therapy after breast-conserving surgery (BCS).

99 teral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS).

100 ry treatment option for most women is breast-conserving surgery (BCS).

101 uate residual tumor immediately after breast-conserving surgery (BCS).

102 lly eligible for either mastectomy or breast-conserving surgery (BCS; n = 125).

103 racteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy or alone

104 Breast-conserving surgery combined with axillary lymph node dis

105 Breast-conserving surgery combined with radiation therapy is no

106 he benefit of radiotherapy (RT) after breast-conserving surgery compared with observation.

107 gnosed breast cancer who were offered breast-conserving surgery consented from September 2006 to Nove

108 To ensure successful breast conserving surgeries, efficient tumour margin resection

109 a cohort of young women who underwent breast-conserving surgery followed by radiotherapy.

110 are comparable to outcomes seen after breast-conserving surgery followed by standard whole-breast irr

111 Radiotherapy (RT) after breast-conserving surgery for early-stage disease has become an

112 regarding the optimal margin width in breast-conserving surgery for invasive breast cancer.

113 d 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocar

114 women from receiving the benefits of breast-conserving surgery, forcing them to choose a mastectomy

115 database of DCIS patients undergoing breast-conserving surgery from 1978 to 2010.

116 At a time when breast-conserving surgery has become more widely used, this sha

117 500 patients treated with APBI after breast-conserving surgery have been published.

118 Although mastectomy and breast conserving surgery have low risk for complications, few

119 The rate of breast-conserving surgery in both states and the correlates of

120 The rate of breast-conserving surgery in both states was much higher than p

121 atment of breast cancer on the use of breast-conserving surgery in clinical practice.

122 Although the rate of breast-conserving surgery in each state was higher than expecte

123 r the procedure, nearly 75% underwent breast-conserving surgery in Massachusetts and nearly half did

124 This method allows axilla-conserving surgery in patients responding well to NST.

125 ing multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer

126 In all patients, breast-conserving surgery included complete gross excision of t

127 Hypofractionated WBI after breast conserving surgery increased among women with early-stag

128 tion of all women who were treated by breast-conserving surgery increased, and because this approach

129 Identifying tumour margins during breast-conserving surgeries is a persistent challenge.

130 Breast-conserving surgery is a more complex treatment than mast

131 Although breast-conserving surgery is a standard approach for patients w

132 east cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radiotherapy

133 Locoregional failure after breast-conserving surgery is associated with increased risk of

134 The surgical margin status after breast-conserving surgery is considered the strongest predictor

135 when invasive local recurrence after breast-conserving surgery is detected.

136 However, its use during tissue-conserving surgery is limited by time-consuming tissue p

137 er, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant should no

138 ammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should no

139 ing fact about local recurrence after breast-conserving surgery is that most occurs in the area of br

140 Breast conserving surgery is the preferred treatment for women

141 Tissue-conserving surgery is used increasingly in cancer treatm

142 fter 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be determined

143 underwent mastectomy (N = 10,471) and breast conserving surgery (N = 16,517).

144 For women who had breast-conserving surgery (n = 49 166), the authors examined re

145 Fifty-nine percent of women underwent breast-conserving surgery, of whom 81% received radiation thera

146 n undergoing an inappropriate form of breast-conserving surgery (omission of radiotherapy, axillary n

147 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or regional b

148 on aid were 25% more likely to choose breast-conserving surgery over mastectomy (risk ratio, 1.25; 95

149 no more likely than others to undergo breast-conserving surgery (P >.2), but these women were more sa

150 DeltaBF cutoff = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04), and the absence of a path

151 wer mortality than that achieved with breast-conserving surgery plus radiation.

152 ernia, and 0.8% and 0.8% after 42,489 breast-conserving surgery procedures.

153 surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after mastectomy,

154 women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation.

155 randomized trials, radiotherapy after breast-conserving surgery reduced mortality from both breast ca

156 Medicare coverage had lower rates of breast-conserving surgery than other women (43.2% vs. 49.2%; ad

157 ely to undergo standard therapy after breast-conserving surgery than other women.

158 urgically treated patients (including breast-conserving surgery), the CPM rate increased by 148% from

159 t DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 188% from

160 </= 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractio

161 our to avoid mastectomy, and to allow breast-conserving surgery to be done.

162 al trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CPM.

163 al trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CPM.

164 radiation); axillary dissection; and breast-conserving surgery versus mastectomy among women undergo

165 Receipt of breast-conserving surgery versus mastectomy.

166 erall rate of radiation therapy after breast-conserving surgery was 80% in the quality improvement pr

167 bservational data, radiotherapy after breast-conserving surgery was associated with much larger morta

168 Breast-conserving surgery was more frequently performed at teac

169 RT was required if breast-conserving surgery was performed but was elective after

170 of patients undergoing mastectomy and breast conserving surgery was performed from the National Surgi

171 Breast-conserving surgery was possible in 66.6% of the patients

172 Breast-conserving surgery was recommended by surgeons and attem

173 The rate of breast-conserving surgery was up to 8.7 percent higher than exp

174 The rates of breast-conserving surgery were 66.7%, 57.9%, and 68.9% in arms

175 ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either w

176 ve ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres in nine

177 primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 months of

178 Rates of breast-conserving surgery were significantly higher in patients

179 Rates of breast-conserving surgery were similar between the two groups (

180 s operable and increases the rates of breast-conserving surgery, while achieving similar long-term cl

181 oximately 3% of patients treated with breast-conserving surgery will have an in-breast local recurren

182 published world medical literature on breast-conserving surgery with and without postoperative irradi

183 tomy with axillary node dissection or breast-conserving surgery with axillary node dissection and rad

184 ges I or II breast cancer, excised by breast conserving surgery with negative margins, were eligible

185 om patients who had been treated with breast-conserving surgery with or without postoperative radiati

186 Compared with breast-conserving surgery with radiation (10-year mortality, 16

187 between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserving the

188 between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserving the

189 CI, 1.02 to 1.73) more likely to get breast-conserving surgery with radiation than other types of tr

190 d on National Guidelines as receiving breast-conserving surgery with radiation therapy and axillary n

191 of definitive surgery (mastectomy or breast-conserving surgery with radiation v breast-conserving su

192 ed that their surgeon did not discuss breast-conserving surgery with them.

193 RO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation in stag

194 atic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy should

195 o metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should

196 carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation therapy (R

197 s lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was more freq

198 t-conserving surgery with radiation v breast-conserving surgery without radiation); axillary dissecti

199 Among women who had breast-conserving surgery, women with SSDI and Medicare coverag